Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mainz Biomed (MYNZ) Common Equity (2020 - 2025)

Mainz Biomed's Common Equity history spans 5 years, with the latest figure at $6.0 million for Q4 2024.

  • For Q4 2024, Common Equity rose 86.09% year-over-year to $6.0 million; the TTM value through Dec 2024 reached $6.0 million, up 86.09%, while the annual FY2024 figure was $6.0 million, 86.09% up from the prior year.
  • Common Equity for Q4 2024 was $6.0 million at Mainz Biomed, up from $3.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $14.1 million in Q4 2022 and bottomed at -$2.7 million in Q4 2020.
  • The 5-year median for Common Equity is $6.0 million (2024), against an average of $5.4 million.
  • The largest annual shift saw Common Equity soared 332.03% in 2021 before it tumbled 76.95% in 2023.
  • A 5-year view of Common Equity shows it stood at -$2.7 million in 2020, then skyrocketed by 332.03% to $6.4 million in 2021, then surged by 121.6% to $14.1 million in 2022, then crashed by 76.95% to $3.2 million in 2023, then surged by 86.09% to $6.0 million in 2024.
  • Per Business Quant, the three most recent readings for MYNZ's Common Equity are $6.0 million (Q4 2024), $3.2 million (Q4 2023), and $14.1 million (Q4 2022).